Abstract
Routine screening of all newborns for inherited disorders began in the 1960s after Horst Bickel had established an effective dietary therapy for phenylketonuria (PKU) and Robert Guthrie introduced a simple bacterial inhibition assay to detect elevated concentrations of phenylalanine in dried blood spots, a type of specimen universally known as the “Guthrie card.” Over time newborn screening was extended to several other treatable metabolic and endocrine disorders including galactosemia, maple syrup urine disease, biotinidase deficiency, hypothyroidism, congenital adrenal hyperplasia, and hemoglobinopathies. Beginning in the late 1990s, the scope of newborn screening has leaped forward exponentially by the introduction of acylcarnitine and amino acid analysis in Guthrie cards by tandem mass spectrometry (MS/MS). This technology has been used in biochemical genetics laboratories for the detection and analysis of acylcarnitines since the 1980s and has become amenable to newborn screening because of the development of automated, high-throughput techniques of sample preparation (typically to butyl esters derivatives) and injection into the instrument, as well as simultaneous quantitative analysis of amino acids and acylcarnitines under 2 min per sample. Amino acids are the building blocks of proteins. Acylcarnitines are formed from free carnitine and acyl-CoA moieties derived from fatty acids and organic acids (which may have been derived from amino acids) through the action of one of several carnitine-acyl-CoA transferases. This multiplex platform therefore enables the concurrent detection of disorders of amino acid, fatty acid, and organic acid intermediary metabolism and thus several of the most prevalent treatable inborn errors of metabolism. The concentrations of amino acids and acylcarnitine species fluctuate in response to many possible metabolic defects leading to complex profiles with more than 60 informative markers that require various degrees of differential diagnosis. In other words, the significant progress achieved at the analytical level has no remedy, or substitute, for the inevitable complexity of post-analytical interpretation. Additional MS/MS applications have been proposed for newborn screening, most notably several enzyme assays for lysosomal storage disorders, and lysophosphatidylcholines for X-adrenoleukodystrophy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hall PL, Marquardt G, McHugh DM, Currier RJ, Tang H, Stoway SD, Rinaldo P (2014) Postanalytical tools improve performance of newborn screening by tandem mass spectrometry. Genet Med 16:889–895
Marquardt G, Currier R, McHugh DM, Gavrilov D, Magera MJ, Matern D et al (2012) Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med 14:648–655
Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P (2007) Reduction of the false positive rate in newborn screening by implementation of MS/MS-based second tier tests: the Mayo Clinic experience (2004–2007). J Inherit Metab Dis 30:585–592
Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S (2015) Newborn screening for lysosomal storage disorders. Sem Perinatol 39:206–216
McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA et al (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 13:230–254
Mørkrid L, Rowe AD, Elgstoen KBP, Olesen JH, Ruijter G, Hall PL et al (2015) Continuous age- and gender-adjusted reference intervals of urinary markers for cerebral creatine deficiency syndromes: a novel approach to the definition of reference intervals. Clin Chem 61:760–768
Rinaldo P, Zafari S, Tortorelli S, Matern D (2006) Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. MRDD Res Rev 12:255–261
Therrell BL, Lloyd-Puryear MA, Camp KM, Mann MY (2014) Inborn errors of metabolism identified via newborn screening: ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab 113:14–26
Turgeon C, Magera MJ, Allard P, Tortorelli S, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Matern D (2008) Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 54:657–664
Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR (eds) (2006) Newborn screening: toward a uniform screening panel and system. Genet Med 8(Supplement):1S–252S
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Matern, D., Rinaldo, P. (2017). Newborn Screening for Inherited Metabolic Disease. In: Hoffmann, G., Zschocke, J., Nyhan, W. (eds) Inherited Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49410-3_36
Download citation
DOI: https://doi.org/10.1007/978-3-662-49410-3_36
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49408-0
Online ISBN: 978-3-662-49410-3
eBook Packages: MedicineMedicine (R0)